Residual disease in axial spondyloarthritis. Facts and issues

Psoriatic arthritis phase 3 trials: larger effects, but for whom?

Hypertrophic Osteoarthropathy Revealing an Esophageal Tumor

Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas

The changing face of axial spondyloarthritis over the last 25 years

Navigating clinical research challenges in spondyloarthritis: Insights from the French Spondyloarthritis Taskforce (FAST)

Early peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort

Axial spondyloarthritis and inflammatory bowel disease: Therapeutic implications

Can we consider a pre-clinical state of axial spondyloarthritis?

Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop

Clinical significance of a self-reported familial occurrence of rheumatoid arthritis among patients with recent-onset arthritis: data from the ESPOIR cohort

Efficacy of Janus kinase inhibitors in rheumatoid arthritis

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

Erratum to "2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis" [Joint Bone Spine 2022;89:105344]

Axial psoriatic arthritis: New entity or clinical form only?

Factors associated with drug-free remission at 5-year in early onset axial spondyloarthritis patients: Data from the DESIR cohort

Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort

Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study

Lymphoma complicating rheumatoid arthritis: results from a French case-control study

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Publisher Correction: Rheumatological features of Whipple disease

Rheumatological features of Whipple disease

Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)

Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)

Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort

Poor assessment of bone mineral density after a forearm fracture in women aged 50 years or older: Data from a French health insurance database

Toward a tailored therapeutic prescription for patients with axial spondyloarthritis

Pregnancy rates and outcomes in early axial spondyloarthritis: An analysis of the DESIR cohort

Prise en charge des patients atteints de maladies rhumatismales pendant la pandémie de COVID-19 : la Société française de rhumatologie répond aux questions fréquentes posées jusqu’en mai 2020

Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III Trials

Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study

Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis?

Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)

New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study

Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France

Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study

Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis?

Real-life golimumab persitence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study, GO-PRACTICE

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study

PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)

Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE

Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study

Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission

Stable efficacy and safety after switching from intravenous to subcutaneous tocilizumab in a cohort of 200 patients in real life conditions

Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

Machine learning reveals the most important psychological and social variables predicting the differential diagnosis of rheumatic and musculoskeletal diseases

Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study

Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study

Treatment with Targeted Therapy in Patients with Psoriatic Arthritis and Inadequate Response to Methotrexate: Proposal for a Rational Strategy

High prevalence of clinical and biological features of metabolic syndrome in patients with epidural lipomatosis: A single-center, retrospective study

Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: results from the MAJIK-SFR registry

Tight control and treat-to-target in axial spondyloarthritis. Where are we?

Clinical stability despite progressive fatty infiltration in patients over 50 years old with full-thickness rotator cuff tears